. 2018 Jan 9;319(2):154–164. doi: 10.1001/jama.2017.19130

Table 1. Overall and Subtype-Specific Breast Cancer Mortality Reductions in 2012 Associated With Screening, Treatment, or Both by Model^a.

Model	Mortality Reduction, %^b			Fraction of Combined Mortality Reduction, %		Relative Contribution to Combined Mortality Reduction, %^c
Model	Associated With Screening Alone	Associated With Treatment Alone	Associated With Screening and Treatment^d	Associated With Screening Alone^e	Associated With Treatment Alone^f	Associated With Screening^g	Associated With Treatment^h
Overall
Dana-Farber	29	28	49	59	57	51	49
Erasmus	18	30	43	41	70	37	63
Georgetown-Einstein	25	37	53	47	69	40	60
MD Anderson	17	29	39	44	73	38	62
Stanford	18	37	50	36	74	33	67
Wisconsin-Harvard	17	49	58	30	84	26	74
Mean	21	35	49	43	71	37	63
By Molecular Subtype
ER+/ERBB2−
Dana-Farber	30	30	52	59	58	50	50
Erasmus	18	34	46	39	73	35	65
Georgetown-Einstein	26	39	54	48	71	40	60
MD Anderson	17	31	42	42	75	36	64
Stanford	19	41	53	35	77	31	69
Wisconsin-Harvard	16	51	59	27	86	24	76
Mean	21	38	51	42	73	36	64
ER+/ERBB2+
Dana-Farber	27	38	57	46	67	41	59
Erasmus	20	42	52	39	82	32	68
Georgetown-Einstein	24	43	58	41	74	36	64
MD Anderson	18	38	46	38	82	32	68
Stanford	17	58	66	26	88	23	77
Wisconsin-Harvard	19	62	71	26	87	23	77
Mean	21	47	58	36	80	31	69
ER−/ERBB2+
Dana-Farber	25	28	49	52	58	47	53
Erasmus	17	28	41	40	68	37	63
Georgetown-Einstein	25	32	52	48	62	43	57
MD Anderson	15	23	33	45	70	39	61
Stanford	17	25	40	42	63	40	60
Wisconsin-Harvard	23	43	55	41	79	34	66
Mean	20	30	45	45	67	40	60
ER−/ERBB2−
Dana-Farber	26	20	40	66	50	57	43
Erasmus	17	22	35	47	64	43	57
Georgetown-Einstein	24	29	46	53	63	45	55
MD Anderson	18	14	27	65	52	56	44
Stanford	18	17	33	53	50	52	48
Wisconsin-Harvard	18	30	42	43	70	38	62
Mean	20	22	37	55	58	48	52

Abbreviations: ER, estrogen-receptor; ERBB2; human epidermal growth factor receptor 2.

^{^a}

The column labels are defined as follows:

^{^b}

Relative to the estimated baseline mortality in 2012.

^{^c}

These columns sum to 100%.

^{^d}

Combined mortality reduction.

^{^e}

Column 2 divided by column 4.

^{^f}

Column 3 divided by column 4.

^{^g}

Column 2 divided by the sum of columns 2 and 3.

^{^h}

Column 3 divided by the sum of columns 2 and 3.

Table 1. Overall and Subtype-Specific Breast Cancer Mortality Reductions in 2012 Associated With Screening, Treatment, or Both by Modela.